Median maximum reversal in evaluable
patients was 100% in first 4 hours†
Most patients achieved complete reversal
as measured by ECT (82%), or dTT (99%)‡
*RE-VERSE AD included data for 503 patients: 301 patients with serious bleeding (Group A) and 202 requiring an urgent procedure (Group B).
†Based on determination for dTT or ECT.
‡In a limited number of patients, elevated coagulation parameters (eg, aPTT or ECT) have been observed 12-24 hours post-dose.
§Accurate as of 06/30/2018. Boehringer Ingelheim Pharmaceuticals, Inc. cannot guarantee the availability of PRAXBIND at the facilities listed on this page. Based on the most current information available to Boehringer Ingelheim Pharmaceuticals, Inc., these institutions have purchased PRAXBIND.
References: 1. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431-441; 1-13 [suppl appendix]. 2. PRAXBIND [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 3. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
Praxbind® (idarucizumab) is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
CL-PB-100001 April 2018
Please click here for full Prescribing Information for PRAXBIND.